All In Biotech

Drug Trial Radar · NCT01231373

Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"

Last checked: Nov 20, 2026Latest source record: Apr 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 235 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

235

Actual

Start

Nov 2010

Primary completion

Sep 2011

Study completion Aug 2014

Sponsor

Lead sponsor
Boston Scientific CorporationIndustry
Sponsor type
Industry
First posted
Nov 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the safety and effectiveness of three different concentrations of an investigational drug, Polidocanol Endovenous Microfoam (PEM) compared to vehicle (inactive solution) in treating the symptoms and appearance of varicose veins.

Conditions

  • Varicose Veins

Interventions

  • polidocanol injectable foam, 0.125%Drug

    active placebo for blinding

  • polidocanol injectable foam, 0.5%Drug

    0.5% polidocanol foam injection

  • polidocanol injectable foam, 1.0%Drug

    1.0% polidocanol foam injection

  • VehicleDrug

    injection of vehicle comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score)Time frame: 8 weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Dothan, Alabama

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Lafayette, Indiana

  • Site not named

    Frederick, Maryland

  • Site not named

    Hunt Valley, Maryland

  • Site not named

    Los Alamos, New Mexico

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Monroeville, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.